Compliance Rate

Compliance Rate 100.0%
Compliant submissions 1
Incompliant submissions 0
Total trials 1

My Organizations' Clinical Trials

Showing 25 of 65 entries
View as:

Combination Chemotherapy Before or After Surgery in Treating Patients With Colorectal Cancer With Liver Metastases That Could Be Removed By Surgery

Phase: N/A Priority: Normal
NCT ID: NCT01189227 Org: User:
Start: 08/31/10 End: 12/31/11 Due: 12/31/12

Clinical Trial of Neoadjuvant Chemotherapy With Atezolizumab or Placebo in Patients With Triple-Negative Breast Cancer Followed After Surgery by Atezolizumab or Placebo

Phase: N/A Priority: Normal
NCT ID: NCT03281954 Org: User:
Start: 12/19/17 End: 11/30/27 Due: 11/30/28

Radiation Therapy (WBI Versus PBI) in Treating Women Who Have Undergone Surgery For Ductal Carcinoma In Situ or Stage I or Stage II Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00103181 Org: User:
Start: 03/31/05 End: 08/31/18 Due: 08/31/19

Fluorouracil, Semustine, and Vincristine Compared With BCG in Treating Patients With Dukes' B or Dukes' C Colon Cancer That Has Been Removed By Surgery

Phase: N/A Priority: Normal
NCT ID: NCT00427570 Org: User:
Start: 09/30/77 End: 05/31/06 Due: 05/31/07

NSABP Biospecimen Discovery Project

Phase: N/A Priority: Normal
NCT ID: NCT01850628 Org: User:
Start: 07/31/13 End: 02/28/22 Due: 02/28/23

Study of Bevacizumab Combined With Capecitabine and Either Oxaliplatin or Irinotecan as First Course of Treatment for Patients With Colorectal Cancer That Has Spread Beyond the Colon

Phase: N/A Priority: Normal
NCT ID: NCT00314353 Org: User:
Start: 03/31/06 End: 06/30/10 Due: 06/30/11

Celecoxib in Preventing Polyps in Patients Who Have Undergone Surgery for Stage I Colon Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00087256 Org: User:
Start: 07/31/04 End: 04/30/06 Due: 04/30/07

Diagnostic Procedures in Detecting Tumor Cells in the Bone Marrow of Patients Undergoing Surgery for Stage I, Stage II, or Stage IIIA Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00089323 Org: User:
Start: 01/31/07 End: 08/31/18 Due: 08/31/19

Therapy With Docetaxel and ZD1839 for Patients Who Have Advanced Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00052169 Org: User:
Start: 01/31/03 End: 09/30/06 Due: 09/30/07

BETH Study: Treatment of HER2 Positive Breast Cancer With Chemotherapy Plus Trastuzumab vs Chemotherapy Plus Trastuzumab Plus Bevacizumab

Phase: N/A Priority: Normal
NCT ID: NCT00625898 Org: User:
Start: 04/30/08 End: 07/31/14 Due: 07/31/15

A Study of Gemcitabine, Epirubicin, and Paclitaxel Combination Chemotherapy Given Before Surgery to Patients With Locally Advanced Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00378313 Org: User:
Start: 11/30/01 End: 11/30/05 Due: 11/30/06

Safety and Effectiveness Study of Chemotherapy and Ziv-aflibercept to Treat Metastatic Colorectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01889680 Org: User:
Start: 11/30/14 End: 05/31/18 Due: 05/31/19

Studying Biological Markers of Fatigue in Women With Residual Invasive Breast Cancer Enrolled on Clinical Trial NSABP-B-45

Phase: N/A Priority: Normal
NCT ID: NCT00914043 Org: User:
Start: - End: 06/30/10 Due: 06/30/11

Therapy With Bevacizumab (BEV), Epirubicin, and Cyclophosphamide Followed by Docetaxel Plus Trastuzumab and BEV Given as Neoadjuvant or Adjuvant Therapy for Women With Locally Advanced HER2 Positive Invasive Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00464646 Org: User:
Start: 05/31/07 End: 05/31/14 Due: 05/31/15

A Study of AC Followed by a Combination of Paclitaxel Plus Trastuzumab or Lapatinib or Both Given Before Surgery to Patients With Operable HER2 Positive Invasive Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00486668 Org: User:
Start: 07/31/07 End: 03/31/17 Due: 03/31/18

Chemotherapy in Treating Women With Breast Cancer That Can Be Surgically Removed

Phase: N/A Priority: Normal
NCT ID: NCT00002707 Org: User:
Start: 12/31/95 End: 02/28/10 Due: 02/28/11

Comparison of Neoadjuvant Chemotherapy With Weekly Paclitaxel or Eribulin Followed by A/C in Women With Locally Advanced HER2-Negative Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01705691 Org: User:
Start: 09/30/12 End: 10/31/15 Due: 10/31/16

Oxaliplatin and Capecitabine With or Without an Hepatic Arterial Infusion With Floxuridine in Treating Patients Who Are Undergoing Surgery and/or Ablation for Liver Metastases Due to Colorectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00268463 Org: User:
Start: 01/31/06 End: 06/30/08 Due: 06/30/09

Combination Chemotherapy in Treating Women With Stage I, Stage II, or Stage IIIA (cT1-3, N0-1, M0) Breast Cancer and Positive Axillary Lymph Nodes

Phase: N/A Priority: Normal
NCT ID: NCT00003782 Org: User:
Start: 03/31/99 End: 12/31/12 Due: 12/31/13

Factors Influencing Decision-Making About the Use of Chemoprevention in Women at Increased Risk for Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01399359 Org: User:
Start: 08/31/11 End: 10/31/14 Due: 10/31/15

Study of Pembrolizumab With Pemetrexed and Oxaliplatin in Chemo-Refractory Metastatic Colorectal Cancer Patients

Phase: N/A Priority: Normal
NCT ID: NCT03626922 Org: User:
Start: 05/15/19 End: 11/30/22 Due: 11/30/23

Study of Neoadjuvant Chemotherapy Plus Trastuzumab and Pertuzumab in HER2-Negative Breast Cancer Patients With Abnormal HER2 Signaling

Phase: N/A Priority: Normal
NCT ID: NCT03412643 Org: User:
Start: 05/14/18 End: 10/30/23 Due: 10/30/24

Cancer Stem Cell Biomarkers as a Predictor of Response to Trastuzumab in Samples From Patients With Breast Cancer Previously Treated in the NSABP-B-31 Trial

Phase: N/A Priority: Normal
NCT ID: NCT01424865 Org: User:
Start: 11/30/11 End: - Due: -

Chemotherapy With or Without Bevacizumab in Treating Women With Stage I, Stage II, or Stage IIIA Breast Cancer That Can Be Removed By Surgery

Phase: N/A Priority: Normal
NCT ID: NCT00408408 Org: User:
Start: 11/30/06 End: 03/31/18 Due: 03/31/19

Identification of Genes That Predict Local Recurrence in Samples From Patients With Breast Cancer Treated on NSABP-B-28

Phase: N/A Priority: Normal
NCT ID: NCT01420185 Org: User:
Start: 10/31/11 End: - Due: -